Member Info for Scinv_temp

Sounds like autoimmune related sensory neuropathy, one of the nasty things can happen to someone following infection or vaccination. It is very rare (and even rarer in chlidren) and unfortunate, doesn't mean it's autism-like though. I get how a distressed parent might make such scenarios to explain what happened but find it hard to believe how it would confuse a physician. Hope you are fewling better now.

CT is a clown ffs

*neat

It's a near way to get a cpi with longer remaining patent life while also doing another job with a mechanism that is shown to be safe, though it generally disappointed in terms of efficacy relative to what was expected when it was a hot topic (20-25 tears ago)

Elrico was also involved in the Telegram group for Synairgen (SNG). Worth going over to that board and asking them how it worked out for them. Hint: It lost 99% of its market value.

People have been using this (under controlled conditions usually) for weight loss as well. Many think that microbiota will be the next big step for treating several conditions. Too early still to affect scancell or anyone else really.

Examples

BRAFi: stratified because for first line at least, BRAF mutation/overactivation needs to be verified before treatment

SCIB1: HLA A2 needs to be verified before treatment

Herceptin: HER2 presence/amplification needs tobe verified (typically histologically)

In other cases purely histological/morphological characteristics may be taken into account that are not necessarily linked to a particular molecular phenotype, but usually stratification is on the molecular level.

So these drugs are off the shelf, but are still stratified (additional characteristics need to be taken into account beyond simply disease type)

Determining if a patient's general health (for example) is good enough for a particualar treatment, though in a way is also stratification, is not typically regarded as such.

*Broad would have been a better word instead of agnostic since obviously they would still be targeted to particular indication(s).

Stratified vaccines means vaccines that are designed to target tumours (or patients) with particular characteristics. De facto this means that they are off the shelf. Agnostic -> Stratified -> Personalised (order of specificity to patient/tumour molecular profile). This could have been a reference to SCIB1. I'm sure if he could reveal something newer than 1 year old data, he would have. Perhaps eventually you will understand how silly (not the word I had in mind but let's keep it civil) SC's data communication strategy is.

Lmao. CT is a bigger clown than inan and whoever doesn't get that is an even bigger one.

A few really eloquent people follow this share, all things considered, that's good. Except the subject matter is not literature.

(Do take my non-response as a positive reaction from me as I see a glimmer of hope that world is not doomed to spiral into absurdity - to extend my comment to touch beyond the matters of this board)

I guess I am not trustworthy but in a very nice way?

What kind of logic is that?

I'll asnwer that for you, the same logic that makes you blind to reasonable arguments.

Ah the good old "they are evil" argument.

If I were you, I would print the comment below, laminate it and read it aloud several times each morning.

CrustyPete

31 Oct 2024 19:53

Posts: 15,823

Price: 13.375

Firstly EE being in control of events is one thing EE, what expectations you choose to communicate to your shareholders is another - the mistake of the previous company mentioned was BoD that you refer to was, that whilst they may never have been in total control of external events, they refused to admit or convey that to shareholders and were perceived as being guilty of overpromising and underdelivering - I had rather hoped that the Scancell BoD were a little more mature in their approach to investor comm's.

So whilst I would not expect "control", EE, but I would certainly expect them to be"well-informed". As I alluded to earlier at this distance I would have expected them to be somewhat more definitive about their expectations; the end of Q4 is only 8 weeks or so away... I would have hoped and expected them to be at least aware of how things are progressing towards that Q4 target. If, even at this distance, it is as you say "beyond their control" then what is to give us any confidence that Q4 is even remotely realistic? If it is likely to be late, I rather hope the BoD will engage in some "expectation management" rather than just let us and the market just swing in the wind.

What is the importance of the 25 weeks Bermuda?

And there is also this one:

Scinv_temp

Posted in: SCLP

Posts: 1,319

Price: 13.50

No Opinion

RE: Timeframes17 Oct 2024 10:12

Give a break EE.

Up to September 2023 we had 15-16 patients recruited and the trial had been running for more than 18 months. So all these generic things that you mentioned were true back then and still remain true now. The question is since they already knew the approximate recruitment rate up to September 2023, which was 16 patients iirc in 18 months, what was the informed and honest hypothesis back then that led them to believe than in the following 3 months they would be able to recruit another 27 patients to reach 43? Even at the extreme assumption that they would stop the trial when 27 patients show response, which takes minimum 5 months including comfirmation (more imo but that's another story), what was the reasonable and honest hypothesis in Sept 2023 that they would have recruited another 16 patients (27 -11) AND treat them AND done first measurement AND confirmed so that they would be able to stop recruitment by end of 2023 and, technically, complete recruitment?

Let me make it perfectly clear, SHE INTENTIONALLY MISLED INVESTORS. And if you think that my comments amount to defamation then BE MY GUEST and send it to her. Happy to argue the same ANYWHERE.

LD did say that and no it did not happen. That's the point.

So she told you that herself🤣🤣🤣🤣

Can you post what she wrote/said *verbatim*?

And by the way, you still haven't replied on the s ib1 recruitment stalling because patients were waiting for iscib1+ uber BS.

The best result is measured throughout the trial FFS. PD exit the trial automatically (unless clinician and patient disagree).